Joshua D. Vardigan

565 total citations
20 papers, 429 citations indexed

About

Joshua D. Vardigan is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Physiology. According to data from OpenAlex, Joshua D. Vardigan has authored 20 papers receiving a total of 429 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 10 papers in Cellular and Molecular Neuroscience and 6 papers in Physiology. Recurrent topics in Joshua D. Vardigan's work include Neuroscience and Neuropharmacology Research (9 papers), Receptor Mechanisms and Signaling (8 papers) and Ion channel regulation and function (7 papers). Joshua D. Vardigan is often cited by papers focused on Neuroscience and Neuropharmacology Research (9 papers), Receptor Mechanisms and Signaling (8 papers) and Ion channel regulation and function (7 papers). Joshua D. Vardigan collaborates with scholars based in United States, United Kingdom and Canada. Joshua D. Vardigan's co-authors include Jason M. Uslaner, Sarah L. Huszar, Pete H. Hutson, John J. Renger, Christopher E. Cannon, Scott D. Kuduk, Peter H. Hutson, Caitlyn McNaughton, Sean M. Smith and Antonella Converso and has published in prestigious journals such as Biological Psychiatry, Pain and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Joshua D. Vardigan

20 papers receiving 422 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joshua D. Vardigan United States	12	302	211	102	80	48	20	429
Kate E. Gilling Germany	11	219 0.7×	257 1.2×	93 0.9×	62 0.8×	48 1.0×	17	461
Takahide Shuto Japan	13	421 1.4×	344 1.6×	184 1.8×	45 0.6×	59 1.2×	24	697
Sophie M. Banas France	9	173 0.6×	259 1.2×	72 0.7×	64 0.8×	45 0.9×	16	480
Fany Panayi France	11	229 0.8×	290 1.4×	90 0.9×	78 1.0×	86 1.8×	16	533
Daniel E. Knutson United States	13	185 0.6×	239 1.1×	53 0.5×	67 0.8×	59 1.2×	28	437
Jane Gartlon United Kingdom	13	243 0.8×	306 1.5×	101 1.0×	80 1.0×	128 2.7×	18	628
Taiichiro Imanishi Japan	11	168 0.6×	208 1.0×	129 1.3×	51 0.6×	68 1.4×	17	422
Tolga Uz United States	12	284 0.9×	73 0.3×	158 1.5×	72 0.9×	60 1.3×	18	440
Maggie D. Lalies United Kingdom	12	247 0.8×	315 1.5×	51 0.5×	75 0.9×	31 0.6×	17	492
Stanley Nawoschik United States	12	454 1.5×	403 1.9×	70 0.7×	82 1.0×	55 1.1×	18	655

Countries citing papers authored by Joshua D. Vardigan

Since Specialization

Citations

This map shows the geographic impact of Joshua D. Vardigan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joshua D. Vardigan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joshua D. Vardigan more than expected).

Fields of papers citing papers by Joshua D. Vardigan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joshua D. Vardigan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joshua D. Vardigan. The network helps show where Joshua D. Vardigan may publish in the future.

Co-authorship network of co-authors of Joshua D. Vardigan

This figure shows the co-authorship network connecting the top 25 collaborators of Joshua D. Vardigan. A scholar is included among the top collaborators of Joshua D. Vardigan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joshua D. Vardigan. Joshua D. Vardigan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Vardigan, Joshua D., Xiaoping Zhou, Thomas W. Rosahl, et al.. (2025). Humanized NaV1.8 rats overcome cross-species potency shifts in developing novel NaV1.8 inhibitors. PubMed. 18. 100182–100182. 1 indexed citations

Vardigan, Joshua D., Chien-Jung Huang, Michelle K. Clements, et al.. (2024). Analgesia and peripheral c-fiber modulation by selective Nav1.8 inhibition in rhesus. Pain. 166(3). 631–643. 3 indexed citations

Breslin, Michael J., Deping Wang, Chien-Jung Huang, et al.. (2024). 2-Aminopyridines as Potent and Selective Na_v1.8 Inhibitors Exhibiting Efficacy in a Nonhuman Primate Pain Model. ACS Medicinal Chemistry Letters. 15(6). 917–923. 3 indexed citations

Smith, Sean M., Dawn Toolan, Monika Kandebo, et al.. (2024). Preclinical evaluation of MK-8189: A novel phosphodiesterase 10A inhibitor for the treatment of schizophrenia. Journal of Pharmacology and Experimental Therapeutics. 392(1). 100047–100047. 1 indexed citations

Ballard, Jeanine, Joshua D. Vardigan, Fuqiang Zhao, et al.. (2021). Translational Pharmacokinetic–Pharmacodynamic Modeling of NaV1.7 Inhibitor MK-2075 to Inform Human Efficacious Dose. Frontiers in Pharmacology. 12. 786078–786078. 5 indexed citations

Lange, Henry S., et al.. (2021). Effects of a novel M4 muscarinic positive allosteric modulator on behavior and cognitive deficits relevant to Alzheimer's disease and schizophrenia in rhesus monkey. Neuropharmacology. 197. 108754–108754. 17 indexed citations

Kraus, Richard L., Fuqiang Zhao, Dan Zhou, et al.. (2021). Na _v 1.7 target modulation and efficacy can be measured in nonhuman primate assays. Science Translational Medicine. 13(594). 15 indexed citations

Ballard, Jeanine, Joshua D. Vardigan, Fuqiang Zhao, et al.. (2020). Application of Pharmacokinetic-Pharmacodynamic Modeling to Inform Translation of In Vitro NaV1.7 Inhibition to In Vivo Pharmacological Response in Non-human Primate. Pharmaceutical Research. 37(10). 181–181. 4 indexed citations

Wang, Xiaohai, Christopher J. A. Daley, Henry S. Lange, et al.. (2020). Pharmacological Characterization of the Novel and Selective α7 Nicotinic Acetylcholine Receptor–Positive Allosteric Modulator BNC375. Journal of Pharmacology and Experimental Therapeutics. 373(2). 311–324. 13 indexed citations

10.

Vardigan, Joshua D., Andrea K. Houghton, Henry S. Lange, et al.. (2018). Pharmacological validation of a novel nonhuman primate measure of thermal responsivity with utility for predicting analgesic effects. Journal of Pain Research. Volume 11. 735–741. 10 indexed citations

11.

Cramer, Paige E., Keith Q. Tanis, Joshua D. Vardigan, et al.. (2017). Aging African green monkeys manifest transcriptional, pathological, and cognitive hallmarks of human Alzheimer's disease. Neurobiology of Aging. 64. 92–106. 39 indexed citations

12.

Vardigan, Joshua D., Henry S. Lange, Spencer J. Tye, et al.. (2016). Behavioral and qEEG effects of the PDE10A inhibitor THPP-1 in a novel rhesus model of antipsychotic activity. Psychopharmacology. 233(13). 2441–2450. 3 indexed citations

13.

Wang, Xiaohai, et al.. (2015). The selective positive allosteric M1 muscarinic receptor modulator PQCA attenuates learning and memory deficits in the Tg2576 Alzheimer's disease mouse model. Behavioural Brain Research. 287. 96–99. 37 indexed citations

14.

Vardigan, Joshua D., Christopher E. Cannon, Marion Wittmann, et al.. (2014). Improved cognition without adverse effects: novel M1 muscarinic potentiator compares favorably to donepezil and xanomeline in rhesus monkey. Psychopharmacology. 232(11). 1859–1866. 44 indexed citations

15.

Smith, Sean M., Jason M. Uslaner, Christopher D. Cox, et al.. (2012). The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey. Neuropharmacology. 64. 215–223. 70 indexed citations

16.

Vardigan, Joshua D., Antonella Converso, Pete H. Hutson, & Jason M. Uslaner. (2011). The Selective Phosphodiesterase 9 (PDE9) Inhibitor PF-04447943 Attenuates a Scopolamine-Induced Deficit in a Novel Rodent Attention Task. Journal of Neurogenetics. 25(4). 120–126. 39 indexed citations

17.

Uslaner, Jason M., Joshua D. Vardigan, Victor N. Uebele, et al.. (2010). T-Type Calcium Channel Antagonism Decreases Motivation for Nicotine and Blocks Nicotine- and Cue-Induced Reinstatement for a Response Previously Reinforced with Nicotine. Biological Psychiatry. 68(8). 712–718. 13 indexed citations

18.

Vardigan, Joshua D., Sarah L. Huszar, Caitlyn McNaughton, Peter H. Hutson, & Jason M. Uslaner. (2010). MK-801 produces a deficit in sucrose preference that is reversed by clozapine, d-serine, and the metabotropic glutamate 5 receptor positive allosteric modulator CDPPB: Relevance to negative symptoms associated with schizophrenia?. Pharmacology Biochemistry and Behavior. 95(2). 223–229. 60 indexed citations

19.

Uslaner, Jason M., Sean M. Smith, Sarah L. Huszar, et al.. (2010). T-type calcium channel antagonism produces antipsychotic-like effects and reduces stimulant-induced glutamate release in the nucleus accumbens of rats. Neuropharmacology. 62(3). 1413–1421. 27 indexed citations

20.

Uslaner, Jason M., et al.. (2009). Combined administration of an mGlu2/3 receptor agonist and a 5-HT2A receptor antagonist markedly attenuate the psychomotor-activating and neurochemical effects of psychostimulants. Psychopharmacology. 206(4). 641–651. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact